Indeed, pharmacological inhibitors of YAP are currently being evaluated in a phase I clinical trial in tumors bearing mutations in Hippo pathway components or YAP/TAZ gene fusions (NCT04857372) and humanized anti-CCN2 antibodies are currently in clinical investigation (ClinicalTrials.gov, NCT01890265) in pancreatic cancer and (Phase III, ClinicalTrials.gov, NCT03955146) fibrotic diseases [84–87]. This evidence concerns the gene CCN2 and familial pancreatic carcinoma.